source
- Neumora Therapeutics halts lead depression drug after two more Phase 3 failures, plans 35% staff cutsNeumora Therapeutics announced that its lead depression candidate will be discontinued after it did not meet primary endpoints in two additional Phase 3 trials. The company said the data were consi…
- Lilly reports early positive results for new JAK2 inhibitor in hard-to-treat myelofibrosisLilly has incorporated a JAK2‑targeting drug originally discovered by Ajax Therapeutics after its recent acquisition. The experimental pill is intended for patients with myelofibrosis, a difficult‑…